3,5-diamino-N-carbamimidoyl-6-(5-cyanobenzofuran-2-yl)pyrazine-2-carboxamide

ID: ALA4527266

PubChem CID: 155544256

Max Phase: Preclinical

Molecular Formula: C15H12N8O2

Molecular Weight: 336.32

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  N#Cc1ccc2oc(-c3nc(C(=O)NC(=N)N)c(N)nc3N)cc2c1

Standard InChI:  InChI=1S/C15H12N8O2/c16-5-6-1-2-8-7(3-6)4-9(25-8)10-12(17)22-13(18)11(21-10)14(24)23-15(19)20/h1-4H,(H4,17,18,22)(H4,19,20,23,24)

Standard InChI Key:  RIWMXTKYCSSHPO-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 25 27  0  0  0  0  0  0  0  0999 V2000
   31.3738   -5.1260    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.3726   -5.9455    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.0807   -6.3545    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   32.7903   -5.9450    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.7875   -5.1224    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.0789   -4.7171    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   33.4987   -6.3525    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   30.6646   -6.3536    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   33.4937   -4.7111    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.2029   -5.1170    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   33.4906   -3.8939    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   34.9091   -4.7058    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.6183   -5.1117    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   34.9060   -3.8886    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   30.6680   -4.7177    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.5830   -3.9054    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   29.9225   -5.0472    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.3774   -4.4410    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.7865   -3.7378    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.3821   -3.0340    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.5688   -3.0322    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.1616   -3.7400    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.5683   -4.4409    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.3460   -3.7395    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.5289   -3.7410    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  4  7  1  0
  2  8  1  0
  5  9  1  0
  9 10  1  0
  9 11  2  0
 10 12  1  0
 12 13  1  0
 12 14  2  0
  1 15  1  0
 15 16  1  0
 16 19  1  0
 18 17  1  0
 17 15  2  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 18  1  0
 24 25  3  0
 22 24  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4527266

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 336.32

Molecular Weight (Monoisotopic): 336.1083

AlogP: 0.55

#Rotatable Bonds: 2

Polar Surface Area: 193.72

Molecular Species: NEUTRAL

HBA: 8

HBD: 5

#RO5 Violations: ┄

HBA (Lipinski): 10

HBD (Lipinski): 8

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.77

CX Basic pKa: 5.97

CX LogP: 0.65

CX LogD: 0.63

Aromatic Rings: 3

Heavy Atoms: 25

QED Weighted: 0.33

Np Likeness Score: -0.48

References

1. Buckley BJ, Majed H, Aboelela A, Minaei E, Jiang L, Fildes K, Cheung CY, Johnson D, Bachovchin D, Cook GM, Huang M, Ranson M, Kelso MJ..  (2019)  6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.,  29  (24): [PMID:31679971] [10.1016/j.bmcl.2019.126753]

Source

Source(1):

• Scientific Literature